Institutional investors hold a majority ownership of VRTX through the 96.07% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended June 2017, these large investors purchased a net $570.8 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 2.2 Million shares of Vertex Pharmaceuticals In...